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Summary Pulmonary lymphangioleiomyomatosis (LAM) is a rare interstitial disorder
affecting exclusively women, and leading to progressive deterioration of lung
function. The disease course is highly variable from one patient to another, but no
clinical predictor of rapid disease progression is currently available. To identify
clinical variables, which could detect patients at risk for rapid lung function decline,
we searched for correlations between the rate of forced expiratory volume in 1 s
(FEV1) decline and clinical features at diagnosis in a retrospective series of 31 cases
of LAM followed for X1 yr. The mean FEV1 decline was 1067143ml/yr or 3.474.6%
predicted FEV1/yr. Among clinical features at diagnosis, only initial values of carbon
monoxide transfer factor (TLCO, P ¼ 0:006) and carbon monoxide transfer
coefficient (KCO, P ¼ 0:0001) were significantly correlated with the rate of FEV1
decline. Lung volumes and FEV1/forced vital capacity ratio at diagnosis were not
predictive of rapid decline. No effect of previous smoking, contraceptive use or
pregnancy on FEV1 decline could be detected. We conclude that low TLCO and KCO
at the time of diagnosis are the best clinical predictors of rapid FEV1 decline in
patients with LAM.
& 2003 Elsevier Ltd. All rights reserved.
Lymphangioleiomyomatosis (LAM) is a rare disorder
of unknown cause affecting exclusively women,
characterised by abnormal proliferation of nonma-
lignant smooth muscle cells (LAM cells).1 In the
lung, LAM cells proliferation in the walls of bronchi,
blood vessels and lymphatics leads to cystic
destruction of the lung parenchyma characterised
by an obstructive ventilatory defect, lung hyperin-
flation, recurrent pneumothorax, and eventually
progressive respiratory insufficiency.2–6 Other man-
ifestations include enlarged thoracoabdominal
lymph nodes, lymphangiectasis, chylothorax, chy-
lous ascites, and renal angiomyolipomas. The
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Although retrospective analyses suggested that pro-
gesterone might be beneficial in some cases,2–4,7,8 no
effective treatment has been established.
The natural course of pulmonary LAM is highly
variable from one patient to another. Some remain
stable for years and even decades with only mild
ventilatory impairment, whereas others experience
rapid disease progression leading to lung transplan-
tation or death within a few years after disease
onset.2,4 Besides a histological score predicting
survival,9 no tools are currently available to detect
patients at risk of rapid disease progression. The
objective of the present study was to identify
clinical factors associated with rapid lung function
decline in patients with LAM, in order to predict
unfavourable outcome at the time of diagnosis.
Such predictors could be especially of interest to
select patients for therapeutic trials using lung
function decline as the main variable, since the
effect of an experimental treatment would be
easier to detect in patients with rapid deterioration
of lung function than in those with stable disease.
Methods
Case recruitment and data collection
This study was undertaken by the Groupe d’Etudes
et de Recherche sur les Maladies ‘‘Orphelines’’
Pulmonaires (GERM‘‘O’’P), a French group dedi-
cated to the study of ‘‘orphan’’ pulmonary dis-
eases, including LAM. In December 1996, a detailed
questionnaire was sent to physicians who had
reported cases of LAM to the GERM‘‘O’’P registry.
Questionnaires were answered by a review of the
medical records. In October 1999, following com-
pletion of our two previous studies,4,10 physicians
were asked to update information on their LAM
patients, especially lung function tests, occurrence
of lung transplantation, and survival. New cases
were also included. This second data collection
ended in April 2000.
Selection of cases
Cases meeting the two following criteria were
eligible for inclusion:
1. Diagnosis of pulmonary LAM, based on:
(a) characteristic pathological features at lung
biopsy or
(b) typical cystic appearance on chest com-
puted tomography (CT) and at least one of
the following: characteristic pathological
findings on lymph node biopsy; typical
angiomyolipoma of the kidney at imaging
and/or histology; chylous ascites with ab-
dominal lymphadenopathy at imaging; or
abdominal lymphangiectasis at lymphangio-
gram.
2. Complete pulmonary function testing per-
formed in stable condition at diagnosis, and
X2 forced expiratory volume in 1 s (FEV1)
measurements performed in stable condi-
tion at least 1 yr apart.
Complete pulmonary function tests included
FEV1, forced vital capacity (FVC), FEV1/FVC, total
lung capacity (TLC), residual volume (RV), single
breath carbon monoxide transfer factor (TLCO) and
coefficient (KCO), and arterial blood gases. All lung
function tests performed during pleural events such
as pneumothorax or chylothorax, and p2 months
after thoracotomy or thoracoscopy, were dis-
carded. Lung function tests performed after lung
transplantation were of course not included in this
analysis.
Determination of the rate of FEV1 decline
For each patient, the rate of FEV1 decline over time
(DFEV1) was determined as the slope of the linear
regression, both in percentage of predicted value
per year (% pred/yr) and in ml/yr. FEV1 gain over
time resulted in a positive DFEV1 value, and FEV1
loss in a negative DFEV1 value. Since the response
to beta-2-agonists was not systematically available,
only pre-bronchodilator measurements were used.
Data analysis
The main independent variable was DFEV1 ex-
pressed in % pred/yr. This unit was preferred to
ml/yr, because it corrects for morphometric varia-
tions among subjects. The following items were
examined in the search for a correlation with
DFEV1: history of smoking, contraceptive use,
pregnancy, age at first symptoms, clinical features
at diagnosis (dyspnoea, pneumothorax, chylous
effusions, lymphadenopathy, and angiomyolipoma),
initial lung function tests, hormonal treatment, and
outcome. To detect a selection bias, we searched
for correlations between DFEV1 and, respectively,
year of first symptoms, year of diagnosis, duration
of lung function follow-up, and number of FEV1
measurements. Correlation between DFEV1 and
continuous variables were analysed by linear
regression and by Spearman’s rank correlation
coefficient. For binary variables, the cases were
separated into two groups according to the
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presence or absence of the studied feature, and
DFEV1 was compared between groups with the
unpaired t-test and the Mann–Whitney test. All
data were expressed as mean7standard deviation.




Thirty-one cases of pulmonary LAM meeting inclu-
sion criteria were available. Twenty-nine have been
previously reported by our group,4,10 and 20 of
them were updated for the present study. Two were
new cases. Diagnoses were made between 1980 and
1998. Diagnostic criteria were met by lung biopsy in
26 cases (84%) and by typical chest CTscan with one
or more additional criteria in the remaining five
cases (16%). The clinical characteristics of the
study population are presented in Table 1, and the
initial lung function tests are summarised in
Table 2. The most frequent abnormality was
reduced TLCO. An obstructive ventilatory defect
(FEV1/FVCo70%) was present in half of the cases.
No patients had respiratory insufficiency at the
time of diagnosis.
Treatment modalities are summarised in Table 3.
Twenty-eight patients (90%) received at least one
hormonal treatment during disease course. Two or
more treatments were used in 12 (39%). Patients
who received progestatives at some point during
disease course (n ¼ 20) had a nonsignificant trend
for lower initial TLCO and KCO as compared to
those who did not receive this therapy (n ¼ 11), but
the two groups were otherwise similar for all
characteristics (data not shown). Likewise, no
significant difference was found between patients
who received antiestrogens (n ¼ 10) as compared
to those who did not (n ¼ 21), and between
patients who were treated with luteinising-hor-
mone-releasing hormone (LHRH) agonists (n ¼ 12),
as compared to those who were not (n ¼ 19; data
not shown).
Three patients eventually underwent lung trans-
plantation. Four patients died, either from pul-
monary LAM (n ¼ 2) or from complications of lung
transplantation (n ¼ 2).
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Table 1 Selected clinical characteristics at diag-
nosis in 31 cases of LAM.
Age at first symptoms (yr) 3579
Age at diagnosis (yr) 3879
History of smoking (%) 37
History of contraceptive use (%) 33
History of pregnancy (%) 70
History of menopause (%) 4
Pneumothorax (%) 55
Chylous effusion (%) 19
Angiomyolipoma (%) 37
Typical chest CT scan (%) 100
Table 2 Initial lung function tests in 31 cases of LAM.
Frequency of abnormal values Mean values
Criterion % of cases Mean7SD
FEV1 (% pred) o80 58 72726
FVC (% pred) o80 42 85718
FEV1/FVC (%) o70 52 83719
TLC (% pred) 4120 10 97719
RV (% pred) 4120 36 119743
TLCO (% pred) o80 87 55720
KCO (% pred) o80 65 65726
PaO2 (mmHg) o75 3 81714
PaCO2 (mmHg) 440 0 3573
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; RV: residual volume; TLCO: carbon
monoxide transfer factor; KCO: carbon monoxide transfer coefficient. n ¼ 31 for all variables except PaO2 and PaCO2 (n ¼ 26).
Table 3 Treatment modalities in 31 cases of LAM.
Progestatives (%) 65
Antiestrogens (%) 33
LHRH agonists (%) 39
Oophorectomy (%) 7
Pleurodesis (%) 48
Lung transplantation (%) 10
Percentages express the frequency of use of each
treatment in the study population. More than one
treatment modality could have been used in each patient.
LHRH: luteinising-hormone-releasing hormone.
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DFEV1
The characteristics of DFEV1 in the whole study
population are presented in Table 4. The standard
error of the 31 individual DFEV1 regression lines
averaged 1.4% pred/yr, thus reflecting good linear-
ity of the relationship in each case. The mean
DFEV1 in the whole study population was 106ml/
yr or 3.4% pred/yr (range: 439 to þ 139ml/yr
and 13.9 to þ 5.6% pred/yr). The average
duration of lung function follow-up was 4.8 yr. In
search of a recruitment bias, DFEV1 was plotted
against, respectively, year of first symptoms, year
of diagnosis, duration of lung function follow-up, or
number of FEV1 measurements, but no correlation
was found (data not shown).
Correlation between DFEV1 and continuous
variables
A significant correlation was found between DFEV1
and, respectively, initial KCO (r ¼ 0:64; P ¼ 0:0001)
and initial TLCO (r ¼ 0:46; P ¼ 0:006) by linear
regression. The correlation coefficient was higher
for KCO than for TLCO. Lower initial TLCO and KCO
were correlated with more negative DFEV1, i.e.
more severe FEV1 decline. The same findings were
obtained when using Spearman’s rank test. No
correlation was found between DFEV1 and, respec-
tively, age at first symptoms, disease duration, initial
FEV1, FVC, FEV1/FVC, TLC, RV, PaO2, and PaCO2.
Correlation between DFEV1 and binary
variables
In this analysis, the study population was divided
into two groups according to the presence or
absence of a given clinical feature, and DFEV1
was compared between groups by the unpaired t-
test. The same procedure was repeated for all
binary variables. No difference in mean DFEV1 was
found between groups according to history of
smoking, pregnancy, and oral contraceptive use.
Similarly, the presence of pneumothorax, chylous
effusion, or angiomyolipoma at diagnosis was not
associated with increased DFEV1. Repeating these
analyses with nonparametric statistics led to the
same conclusions. Patients who received progesta-
tive treatment at some point during disease course
tended to have a more negative DFEV1 as compared
to patients who did not receive such therapy,
although the difference did not reach statistical
significance. Patients who received LHRH agonists
also had a nonsignificant trend for more negative
DFEV1 as compared to patients who did not receive
this treatment. The five patients who either
required lung transplantation or died tended to
have a more negative DFEV1 compared to the
others, although the difference did not reach
statistical significance.
Discussion
The main finding of the present study is that low KCO
and TLCO at the time of diagnosis correlated with
rapid FEV1 decline in patients with LAM, whereas all
other spirometric and clinical variables at diagnosis
were not predictive of rapid FEV1 decline.
Reduced initial TLCO has been previously shown
to correlate with rapid FEV1 decline in smokers,
11
greater deterioration of gas exchange in idiopathic
pulmonary fibrosis,12 and poorer survival in
COPD.13–15 In LAM, cross-sectional analyses showed
that TLCO correlates with disease severity at
imaging,16,17 a positive response to bronchodila-
tors,18 and a histological score of parenchymal
involvement,18 which in turn predicted survival.9
Taken together, these two studies9,18 suggest that a
relationship exists between initial TLCO and prog-
nosis in LAM. Our data are consistent with these
observations. Although our findings are insufficient
to allow an accurate quantitative prediction of
FEV1 decline in LAM, they could be useful to
identify patients at risk for rapid deterioration of
lung function, in spite of initially preserved lung
volumes. Therefore, complete pulmonary function
tests including TLCO and KCO should be performed
in all cases of LAM at the time of diagnosis.
We did not find any correlation between FEV1
decline and initial FEV1 or other spirometric
variables at diagnosis. Interestingly, the mean
values of initial FEV1 and initial KCO were very
similar (65% and 72% of predicted, respectively), as
were the percentage of abnormal values for these
two variables (58% and 65% of cases below 80% of
predicted, respectively). These similarities con-
trasted with the fact that initial KCO was strongly
correlated with DFEV1, whereas initial FEV1 was
not. These data confirm previous observations8 and
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Table 4 Characteristics of DFEV1 in 31 cases of
LAM.
Mean7SD Median
DFEV1 (ml/yr) 1067143 75
DFEV1 (%pred/yr) 3.474.6 2.4
FEV1 follow-up duration (yr) 4.873.7 3.9
Number of FEV1 measurements 6.473.5 5
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suggest that abnormal lung volumes or an obstruc-
tive ventilatory defect at the time of diagnosis are
not necessarily associated with more rapid dete-
rioration of lung function in LAM.
How the gas exchange abnormalities and, re-
spectively, obstructive ventilatory defect evolve
over time in the natural course of LAM is not
precisely known at the present time. They might
start to decline at different time points and evolve
at different rates, so that KCO could be an earlier
and more sensitive marker of disease progression
than spirometry. Studying KCO decline in LAM
would be of great interest, but we could not
address this issue in the present study due to the
lack of follow-up data. Whether low initial KCO
correlates with survival needs to be addressed in a
larger population.
No clear relationship has been demonstrated so
far between smoking, pregnancy, or contraceptive
use and the development or rate of progression of
pulmonary LAM. Likewise, we could not detect an
influence of these characteristics on FEV1 decline in
the present study. However, a weak correlation
could have been missed due to small sample size.
Whether hormonal treatment has any therapeu-
tic effect on lung function in LAM remains
controversial. In the only study, which retrospec-
tively addressed this issue, a favourable effect of
progesterone on FEV1 decline was observed in a
subgroup, but this did not reach statistical sig-
nificance in the whole study population.8 Should
progesterone have any therapeutic effect, one
would expect treated patients to have a milder
FEV1 decline. In contrast, a trend for the opposite
was observed in the present study, both for
progesterone and for LHRH agonists. No selection
bias was found in our study population by compar-
ing patients who received either one of these
treatments with those who did not. Therefore, the
most likely explanation for this nonsignificant trend
is that rapidly deteriorating patients were more
prone to be treated, in an attempt to minimise the
worsening of their lung function. Because of great
intraindividual variations of treatment over time in
most cases, a detailed analysis of the effect of a
given treatment on the rate of FEV1 decline could
not be performed in this study.
Only two studies have previously analysed FEV1
decline in LAM.8,18 The mean rate of FEV1 decline in
our population was 106ml/yr, which is very similar
to the findings of these two previous studies.8,18
This confirms that, on average, there is accelerated
FEV1 decline in LAM. In comparison, FEV1 declines
approximately by 30ml/yr in non- or former
smokers, and 60ml/yr in active smokers.19–21
Similarly to previous series,8,18 there was a wide
interindividual variation of DFEV1 in our popula-
tion. These concordant data from several LAM
populations suggest that this heterogeneity in
FEV1 decline truly reflects the variable nature of
the disease course from one patient to another.
Despite the retrospective nature of our study and
the small number of cases, we could not detect any
significant selection bias which could have altered
our findings. We searched for correlations between
DFEV1 and, respectively, year of first symptoms,
year of diagnosis, FEV1 follow-up duration, or the
number of FEV1 measurements. No such relation-
ship was found, suggesting that our study popula-
tion has not been biased by underreporting of older
cases with unfavourable outcome, or selection of
long survivors with stable disease and long follow-
up. We used only baseline FEV1 measurements
without beta-2-agonists, since response to bronch-
odilators was not systematically available.
Although a mild effect of beta-2-agonists on
obstructive ventilatory impairment has been re-
ported in a minority of patients with LAM,6,18,22
there are no data suggesting that such therapy may
modify the natural course of the disease. We
therefore believe that our DFEV1 calculation would
not have been affected by using post-bronchodi-
lator FEV1 measurements instead of pre-broncho-
dilator values. Finally, we believe that hormonal
treatments did not bias our findings, for the
following reasons. First, no treatment has proved
its efficacy in LAM at the present time. Secondly, no
significant difference was found between the
various treatment subgroups. Thirdly, patients
who received a treatment intended to improve
their lung function did not disclose a milder FEV1
decline but a trend for the opposite was even
observed.
In summary, this study shows that lower TLCO
and KCO at the time of diagnosis were strongly
correlated with more rapid FEV1 decline in
pulmonary LAM. These data may prove useful to
identify patients at risk for rapid deterioration of
lung function, in spite of apparently preserved lung
volumes at diagnosis. These data could also help to
select patients for future therapeutic trials using
the rate of FEV1 decline as the main outcome
variable. Hence, the effect of an experimental
treatment on this variable would be easier to
detect in patients with rapid deterioration than in
those with stable disease.
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